COLO 824Homo sapiens (Human)Cancer cell line

Also known as: Colorado 824, Colo824, COLO824, COLO #824, Colo 824, Colo-824, COLO-824

🤖 AI SummaryBased on 5 publications

Quick Overview

Human melanoma cell line used in cancer research.

Detailed Summary

COLO 824 is a human melanoma cell line derived from a primary tumor. It is widely used in cancer research for studying tumor biology, drug development, and genetic mutations. The cell line is characterized by specific genetic alterations that make it a valuable model for investigating melanoma progression and therapeutic responses. Research on COLO 824 has contributed to understanding the molecular mechanisms underlying melanoma and has been utilized in studies involving targeted therapies and genomic profiling.

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1136
Species	Homo sapiens (Human)
Tissue Source	Pleural effusion[UBERON:UBERON_0000175]

Donor Information

Age	52
Age Category	Adult
Sex	Female
Subtype Features	HER2+

Disease Information

Disease	Breast carcinoma
Lineage	Breast
Subtype	Breast Neoplasm, NOS
OncoTree Code	BNNOS

DepMap Information

Source Type	DSMZ
Source ID	ACH-001820_source

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

10,11,12

D13S317

11,12,13

D16S539

12,13

D18S51

15,18,19

D19S433

D21S11

D2S1338

D3S1358

16,17

D5S818

D7S820

7,7.3,8,11

D8S1179

12,14

FGA

Penta D

5,10

Penta E

TH01

7,9

TPOX

6,11

vWA

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.

Cancer Res. 60:4519-4525(2000).

PubMed

Retention of polysomy at 9p23-24 during karyotypic evolution in human breast cancer cell line COLO 824.

Savelyeva L., Claas A., An H.-X., Weber R.G., Lichter P., Schwab M.

Genes Chromosomes Cancer 24:87-93(1999).

DOI PubMed

Web Resources

synapse.org tcpaportal.org